H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Lisata Therapeutics (LSTA – Research Report) today and set a price target of $15.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Joseph Pantginis has given his Buy rating due to a combination of factors, primarily focusing on Lisata Therapeutics’ strategic collaboration with GATC Health. This partnership is set to enhance drug development by leveraging GATC’s advanced A.I. platform, which is designed to optimize and de-risk the development process for certepetide across multiple indications. The collaboration aims to identify potential new indications with a high likelihood of success, thereby strengthening Lisata’s pipeline.
Furthermore, the collaboration extends to the identification of combination therapies and operational partnerships for GATC’s own drug candidates, including those targeting opioid addiction and other significant health issues. This strategic alliance not only accelerates Lisata’s drug development timeline but also positions the company to benefit financially through milestone fees and royalties from successfully commercialized products. These factors collectively contribute to Pantginis’s confidence in Lisata’s growth potential and justify the Buy rating.